"Angiopoietin-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An angiopoietin that is closely related to ANGIOPOIETIN-1. It binds to the TIE-2 RECEPTOR without receptor stimulation and antagonizes the effect of ANGIOPOIETIN-1. However its antagonistic effect may be limited to cell receptors that occur within the vasculature. Angiopoietin-2 may therefore play a role in down-regulation of BLOOD VESSEL branching and sprouting.
| Descriptor ID |
D042702
|
| MeSH Number(s) |
D12.644.276.100.100.200 D12.776.467.100.100.200 D23.529.100.100.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Angiopoietin-2".
Below are MeSH descriptors whose meaning is more specific than "Angiopoietin-2".
This graph shows the total number of publications written about "Angiopoietin-2" by people in this website by year, and whether "Angiopoietin-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 2 | 2 |
| 2003 | 1 | 1 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 1 | 3 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiopoietin-2" by people in Profiles.
-
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology. 2024 Jun; 131(6):708-723.
-
Utility of serum angiopoietin-2 as diagnostic marker of hepatocellular carcinoma: A systematic review and diagnostic test accuracy meta-analysis. Clin Res Hepatol Gastroenterol. 2022 05; 46(5):101909.
-
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022 02 19; 399(10326):741-755.
-
Association of Pre-Transplant Angiopoietin-2 Index with the Risk of Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation Turk J Haematol. 2022 02 23; 39(1):61-65.
-
Associations of Angiopoietins With Heart Failure Incidence and Severity. J Card Fail. 2021 07; 27(7):786-795.
-
Non-genetic cell-surface modification with a self-assembling molecular glue. Chem Commun (Camb). 2021 Feb 15; 57(12):1470-1473.
-
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019 08; 126(8):1155-1170.
-
Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur J Cancer. 2017 04; 75:213-221.
-
Variants in angiopoietin-2 (ANGPT2) contribute to variation in nocturnal oxyhaemoglobin saturation level. Hum Mol Genet. 2016 12 01; 25(23):5244-5253.
-
Elevated Angiopoietin-2 Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding. Circulation. 2016 Jul 12; 134(2):141-52.